GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Benlysta (belimumab) Analytical Perspective • In-depth Benlysta (belimumab) Market Assessment This report provides a detailed market assessment of Benlysta (belimumab) in Seven Major Markets, i ...

A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...

Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific ...

Belimumab was the first FDA-approved medication specifically designed for the treatment of lupus. Learn what you need to know about belimumab. Read the study See More: Research news , Treatment news ...

Patients in the belimumab group outpaced those on standard immunotherapy as early as 3 months in meeting the primary outcome and were more likely to sustain it through 24 months (HR = 0.631; 95% ...

Joan T Merrill, MD, from the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues evaluated the long-term safety profile of belimumab for SLE. Patients were randomized to receive ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus (SLE) when added to standard therapy, according to study results ...

A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New ...

Belimumab treatment resulted in at least 50% reduction in dsDNA antibodies in 30% of patients, whereas just 17% of subjects treated with placebo experienced this level of reduction.